ONCAlert | 2018 Gastrointestinal Cancers Symposium

Encouraging Findings With Ribociclib in HR+ Breast Cancer

Harold J. Burstein, MD, PhD
Published Online: 5:59 PM, Tue December 20, 2016

Harold J. Burstein, MD, PhD, institute physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CDK 4/6 inhibitor ribociclib and its clinical activity in patients with hormone receptor (HR)-positive breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.